Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chimerix Inc
(NQ:
CMRX
)
0.9050
+0.0009 (+0.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chimerix Inc
< Previous
1
2
Next >
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
November 11, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 07, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
November 01, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
August 06, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 30, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
May 01, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
April 24, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Appoints Marc D. Kozin to Board of Directors
March 21, 2024
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
February 29, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024
February 22, 2024
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Appoints Lisa Decker to Board of Directors
December 29, 2023
Seasoned Industry Executive Brings More Than 25 Years of Leadership and Business Development Experience
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
December 04, 2023
Proven Leader Brings More Than 25 Years of Financial Experience
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 24, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
November 16, 2023
Seasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business Development
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
November 02, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
October 26, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Participate in Upcoming Investor Conferences
September 05, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
August 16, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
August 03, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
July 27, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
June 27, 2023
From
Chimerix, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.